157 related articles for article (PubMed ID: 26521099)
1. Murine colitis treated with multitargeted tyrosine kinase inhibitors.
Knod JL; Crawford K; Dusing M; Frischer JS
J Surg Res; 2016 Feb; 200(2):501-7. PubMed ID: 26521099
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor receptor-2 inhibition in experimental murine colitis.
Knod L; Donovan EC; Chernoguz A; Crawford KM; Dusing MR; Frischer JS
J Surg Res; 2013 Sep; 184(1):101-7. PubMed ID: 23688787
[TBL] [Abstract][Full Text] [Related]
3. Mouse strain influences angiogenic response to dextran sodium sulfate-induced colitis.
Knod JL; Crawford K; Dusing M; Frischer JS
J Surg Res; 2014 Jul; 190(1):47-54. PubMed ID: 24793451
[TBL] [Abstract][Full Text] [Related]
4. [Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Török S; Döme B
Magy Onkol; 2012 Mar; 56(1):3-15. PubMed ID: 22403757
[TBL] [Abstract][Full Text] [Related]
5. Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
Beuselinck B; Lerut E; Wolter P; Dumez H; Berkers J; Van Poppel H; Joniau S; Oyen R; De Wever L; Strijbos M; Paridaens R; Schöffski P
Clin Genitourin Cancer; 2014 Oct; 12(5):e205-14. PubMed ID: 24861951
[TBL] [Abstract][Full Text] [Related]
6. Metastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case report.
Linassier C; Carmier D; Combe P; D'Arcier BF; Bruyere F; Narciso B
Anticancer Res; 2012 Feb; 32(2):697-700. PubMed ID: 22287765
[TBL] [Abstract][Full Text] [Related]
7. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
Scartozzi M; Faloppi L; Svegliati Baroni G; Loretelli C; Piscaglia F; Iavarone M; Toniutto P; Fava G; De Minicis S; Mandolesi A; Bianconi M; Giampieri R; Granito A; Facchetti F; Bitetto D; Marinelli S; Venerandi L; Vavassori S; Gemini S; D'Errico A; Colombo M; Bolondi L; Bearzi I; Benedetti A; Cascinu S
Int J Cancer; 2014 Sep; 135(5):1247-56. PubMed ID: 24510746
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models.
Zhu XD; Sun HC; Xu HX; Kong LQ; Chai ZT; Lu L; Zhang JB; Gao DM; Wang WQ; Zhang W; Zhuang PY; Wu WZ; Wang L; Tang ZY
Angiogenesis; 2013 Oct; 16(4):809-20. PubMed ID: 23716000
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
[TBL] [Abstract][Full Text] [Related]
11. Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease.
Punekar S; Zak S; Kalter VG; Dobransky L; Punekar I; Lawler JW; Gutierrez LS
Pathobiology; 2008; 75(1):9-21. PubMed ID: 18334835
[TBL] [Abstract][Full Text] [Related]
12. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N
J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017
[TBL] [Abstract][Full Text] [Related]
13. Signaling inhibitors in metastatic renal cell carcinoma.
Escudier B
Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
[TBL] [Abstract][Full Text] [Related]
14. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis.
Scaldaferri F; Vetrano S; Sans M; Arena V; Straface G; Stigliano E; Repici A; Sturm A; Malesci A; Panes J; Yla-Herttuala S; Fiocchi C; Danese S
Gastroenterology; 2009 Feb; 136(2):585-95.e5. PubMed ID: 19013462
[TBL] [Abstract][Full Text] [Related]
15. Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
Denorme M; Yon L; Roux C; Gonzalez BJ; Baudin E; Anouar Y; Dubessy C
Cancer Lett; 2014 Oct; 352(2):236-44. PubMed ID: 25016061
[TBL] [Abstract][Full Text] [Related]
16. Anti-VEGF therapy reduces intestinal inflammation in Endoglin heterozygous mice subjected to experimental colitis.
Ardelean DS; Yin M; Jerkic M; Peter M; Ngan B; Kerbel RS; Foster FS; Letarte M
Angiogenesis; 2014 Jul; 17(3):641-59. PubMed ID: 24510304
[TBL] [Abstract][Full Text] [Related]
17. Promoting inflammatory lymphangiogenesis by vascular endothelial growth factor-C (VEGF-C) aggravated intestinal inflammation in mice with experimental acute colitis.
Wang XL; Zhao J; Qin L; Qiao M
Braz J Med Biol Res; 2016; 49(5):e4738. PubMed ID: 27074165
[TBL] [Abstract][Full Text] [Related]
18. Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling.
Kojonazarov B; Sydykov A; Pullamsetti SS; Luitel H; Dahal BK; Kosanovic D; Tian X; Majewski M; Baumann C; Evans S; Phillips P; Fairman D; Davie N; Wayman C; Kilty I; Weissmann N; Grimminger F; Seeger W; Ghofrani HA; Schermuly RT
Int J Cardiol; 2013 Sep; 167(6):2630-7. PubMed ID: 22854298
[TBL] [Abstract][Full Text] [Related]
19. [Oral drugs inhibiting the VEGF pathway].
Ropert S; Mir O; Armand JP
Bull Cancer; 2007 Jul; 94 Spec No():S180-90. PubMed ID: 17846003
[TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenic therapy: concept to clinic.
Young RJ; Reed MW
Microcirculation; 2012 Feb; 19(2):115-25. PubMed ID: 22078005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
